PMID: 18152338Jul 1, 1949

Observations on the release of serum fibrinolysin by specific antigen, peptone, and certain polysaccharides

The Journal of Experimental Medicine
G UNGAR, S H MIST

Abstract

FORMATION OF FIBRINOLYSIN FROM ITS INACTIVE PRECURSOR IN SERUM WAS OBSERVED UNDER THE FOLLOWING CONDITIONS: (a) by adding the specific antigen to serum from sensitized guinea pigs; (b) by mixing normal guinea pig serum with peptone, agar, hyaluronic acid, chondroitinsulfuric acid, glycogen, pneumococcal polysaccharides, and heparin. Activation of profibrinolysin by these agents differs from chloroform or streptokinase activation in that it requires the presence of some serum constituent non-precipitable with the euglobulin fraction and destroyed by heating at 56 degrees C. The bearing of these observations on the mechanism of anaphylactic and anaphylactoid reactions is discussed. The findings reported support the concept that proteolysis is part of the process determining the release of histamine and other toxic products. It is suggested that the presence of fibrinokinase may be responsible for the toxicity of serum induced in vitro by a number of agents.

References

Dec 15, 1944·The Journal of Physiology·G Ungar

Citations

Jan 1, 1969·Naunyn-Schmiedebergs Archiv Für Pharmakologie·W Vogt, J Lyncker
Jan 11, 1964·Nature·S BOYDEN
Jan 19, 1961·The New England Journal of Medicine·S I COHEN, R WARREN
Jun 1, 1952·The Journal of Experimental Medicine·J COLGANL L MILLER
Jan 1, 1958·Vox Sanguinis·T ASTRUB
Dec 7, 1957·Acta Physiologica Scandinavica·E S OLESEN
Jun 28, 1968·Annals of the New York Academy of Sciences·T Astrup
Jan 1, 1961·Scandinavian Journal of Clinical and Laboratory Investigation·E S OLESEN
Jan 1, 1955·Acta Allergologica·E R TRETHEWIE
Jan 1, 1981·Annals of the New York Academy of Sciences·M L Tiffany, J A Penner
Jan 1, 1951·The Journal of Allergy·W C SPAIN, M B STRAUSS
Mar 1, 1953·The Journal of Allergy·R R SOICHERB ROSE
Jun 26, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·E L Becker
May 1, 1966·Analytical Biochemistry·H RosenkrantzA P Truant
Apr 1, 1956·Experimental Cell Research·P PERLMANN
Jan 1, 1952·Acta Physiologica Scandinavica·S MULLERTZ
Jan 1, 1959·Acta Pharmacologica Et Toxicologica·E S OLESEN
May 1, 1965·The British Journal of Dermatology·H IVEI A MAGNUS
Sep 1, 1955·Klinische Wochenschrift·W SANDRITTER, H HERMANN
Jun 15, 1951·Klinische Wochenschrift·T HALSE
Feb 4, 1963·Annals of the New York Academy of Sciences·W ANTOPOL, C CHRYSSANTHOU
Dec 1, 1956·British Journal of Pharmacology and Chemotherapy·C G HAINING
Jan 1, 1962·Acta Pharmacologica Et Toxicologica·E S OLESEN
Apr 1, 1965·Klinische Wochenschrift·W RAAB, E KAISER
Jan 1, 1962·Archiv für klinische und experimentelle Dermatologie·W P HERRMANN, K H SCHULZ
Jan 1, 1959·Acta Pharmacologica Et Toxicologica·E S OLESEN

Related Concepts

Blood
Antithrombin I

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.